French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
Summary
The company is slated to begin clinical trials in the U.S. in mid-2025.This crucial funding will enable AdipoPharma to accelerate its clinical development, marking a major milestone in the journey toward bringing a first-in-class compound to the market that directly targets insulin resistance, the root cause of Type 2 diabetes.Alain Parthoens, CEO of Newton Biocapital, said: AdipoPharmas mission to deliver a groundbreaking Type 2 diabetes treatment focused on insulin resistance could significantly improve the lives of millions globally. Were delighted to support the company as it embarks on Phase 1 trials in the months ahead.Amy Salzhauer, managing Partner at Good Growth Capital said: PATAS is the first, therapeutic breakthrough for Type 2 diabetes treatment in more than a decade. By restoring glucose uptake and utilization in impaired adipocytes, PATAS, reboots healthy lipid biosynthesis, leading to improved glycated hemoglobin (HbA1c) levels as well as addressing the complications of the disease including diabetic neuropathy, cardiovascular dysfunction, liver disease, and muscle loss.The company was founded by its President and CEO, Vincent Marion, PhD, MSc, a biochemist by training, a researcher at INSERM, the French National Institute for Health and Medical Research, and the former deputy director of the Laboratory of Medical Genetics in Strasbourg. Marion has assembled a team of high-profile, experienced pharmaceutical executives, former senior FDA members, and academic scientists to lead the development of PATAS. The company was established in July 2022 to commercialize the work of its founder, Dr. Vincent Marion, PhD, MSc, biochemist by training and researcher at INSERM, the French National Institute for Health and Medical Research.AdipoPharma SAS is headquartered in Strasbourg, France, with offices in Pittsburgh Pennsylvania, USA and Gosselies, Belgium.